Patient-Reported Outcomes From a Phase 4, Multicenter, Randomized, Double-blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus
mediaposted on 2021-03-05, 17:03 authored by Anca D. Askanase, George J. Wan, Mary P. Panaccio, Enxu Zhao, Julie Zhu, Roman Bilyk, Richard A. Furie
Article full text
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.